You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsing remitting multiple sclerosis (RRMS)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Not yet recruiting
  • Relapsing-remitting Multiple Sclerosis (RRMS)
    • (no location specified)
    Apr 11, 2023

    Assess New Participant's Perspectives Beyond Clinical Efficacy

    Not yet recruiting
    • Multiple Sclerosis, Relapsing-Remitting
      • (no location specified)
      Nov 7, 2023

      Describe Switching FromFirst- or Second-line Disease Modifying

      Not yet recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • (no location specified)
        Dec 12, 2022

        Multiple Sclerosis Trial (Natalizumab)

        Not yet recruiting
        • Multiple Sclerosis
        • (no location specified)
        Jun 21, 2023

        Multiple Sclerosis, Relapsing-Remitting Trial in Washington (NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS)

        Completed
        • Multiple Sclerosis, Relapsing-Remitting
        • NeuroQuant
        • +3 more
        • Washington, District of Columbia
          The George Washignton University
        Jan 4, 2023

        Multiple Sclerosis Trial in Shreveport (Interferon beta 1a, oral doxycycline)

        Completed
        Has Results
        • Multiple Sclerosis
        • Interferon beta 1a, oral doxycycline
        • Shreveport, Louisiana
          LSU Health Sciences Center Shreveport
        Oct 11, 2022

        Multiple Sclerosis, Neurogenic Bladder Trial in Lubbock (vaginal estriol)

        Completed
        Has Results
        • Multiple Sclerosis
        • Neurogenic Bladder
        • vaginal estriol
        • Lubbock, Texas
          Texas Tech University Health Sciences Center
        Aug 25, 2022

        Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled

        Active, not recruiting
        • Relapsing Remitting Multiple Sclerosis (RRMS)
        • Pegylated interferon beta-1a
        • Interferon Beta-1A Prefilled Syringe
        • Tehran, Iran, Islamic Republic of
          Sina Hospital
        Feb 5, 2022

        Relapsing-remitting Multiple Sclerosis (RRMS) Trial in New York (BeCare application)

        Recruiting
        • Relapsing-remitting Multiple Sclerosis (RRMS)
        • BeCare application
        • New York, New York
          Mount Sinai Hospital
        Dec 13, 2021

        Relapsing Remitting Multiple Sclerosis Trial (Laquinimod, Avonex®)

        Withdrawn
        • Relapsing Remitting Multiple Sclerosis
        • (no location specified)
        Nov 5, 2021

        Lesion Load and Location in Relation to Cognition, Fatigue and

        Completed
        • Relapsing Remitting Multiple Sclerosis
        • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
        • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
        • Assiut, Egypt
          Eman Khedr
        Oct 27, 2022

        Imaging Interplay Between Axonal Damage and Repair in Multiple

        Recruiting
        • Multiple Sclerosis (MS)
        • +3 more
        • MRI
        • +2 more
        • Basel, Switzerland
          University Hospital Basel, Department of Neurology
        Dec 15, 2021

        Mechanistic Studies of Teriflunomide in RRMS

        Active, not recruiting
        • Relapsing Remitting Multiple Sclerosis
        • Ann Arbor, Michigan
          University of Michigan
        Jul 27, 2022

        Neurodegeneration in Multiple Sclerosis -Preclinical Study

        Not yet recruiting
        • Relapsing-Remitting Multiple Sclerosis (RRMS)
        • +2 more
        • Peripheral blood withdrawal
        • Pozzilli, Isernia, Italy
        • +2 more
        Feb 15, 2022

        Quality of Life in Clinical Practice in Germany for

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
          • Dresden, Saxony, Germany
            Universitätsklinikum Dresden, MS Ambulanz
          Apr 12, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in Kocaeli (EK-12, INF beta-1a)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Kocaeli, Turkey
            Kocaeli University, Faculty of Medicine, Department of Neurology
          Jul 23, 2021

          Multiple Sclerosis, Relapsing-Remitting Trial in Yvoir (Multiparametric assessment)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Multiparametric assessment
          • Yvoir, Namur, Belgium
            CHU UCL Namur site Godinne
          Aug 19, 2022

          Multiple Sclerosis Trial in Ashkelon, Haifa, Tel Aviv (GA Depot 80 mg, GA Depot 40 mg)

          Active, not recruiting
          • Multiple Sclerosis
          • GA Depot 80 mg
          • GA Depot 40 mg
          • Ashkelon, Israel
          • +2 more
          Aug 9, 2021

          Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)

          Terminated
          • Relapsing Remitting Multiple Sclerosis
          • Pleneva TM BGC20-0134
          • Placebo
          • Gent, Belgium
          • +34 more
          Jun 2, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in Bordeaux (Clinical assessment, Ecological evaluation, Neuropsychological

          Active, not recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Clinical assessment
          • +4 more
          • Bordeaux, France
            CHU de Bordeaux - Service de neurologie
          Feb 2, 2022

          Multiple Sclerosis, Relapsing-Remitting Trial in France (drug, procedure, behavioral)

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
          • Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
          • +4 more
          • Besançon, France
          • +3 more
          Oct 18, 2021

          Multiple Sclerosis Trial in Worldwide (Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon)

          Active, not recruiting
          Has Results
          • Multiple Sclerosis
          • Alemtuzumab GZ402673
          • +11 more
          • Wien, Austria
          • +20 more
          Jun 16, 2022

          Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)

          Recruiting
          • Relapse Remitting Multiple Sclerosis
          • Chandler, Arizona
          • +16 more
          Jan 13, 2023

          Relapsing-Remitting Multiple Sclerosis (RRMS) Trial in Worldwide (IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo)

          Active, not recruiting
          Has Results
          • Relapsing-Remitting Multiple Sclerosis (RRMS)
          • IMU-838 (30 mg/day)
          • +3 more
          • Blagoevgrad, Bulgaria
          • +37 more
          Jan 19, 2022

          Multiple Sclerosis Trial in Montpellier (Magnetic Resonance Imaging, Blood withdrawal, Neuropsychological tests)

          Not yet recruiting
          • Multiple Sclerosis
          • Magnetic Resonance Imaging
          • +2 more
          • Montpellier, France
            Neurology Department, Hopital Gui de Chauliac
          Jul 18, 2023